Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
出版年份 2017 全文链接
标题
Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
作者
关键词
Alanine aminotransferase, Canagliflozin, Hepatic function, Japan, Type 2 diabetes mellitus
出版物
JOURNAL OF GASTROENTEROLOGY
Volume 53, Issue 1, Pages 140-151
出版商
Springer Nature
发表日期
2017-07-01
DOI
10.1007/s00535-017-1364-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
- (2016) Takamasa Ohki et al. CLINICAL DRUG INVESTIGATION
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
- (2016) L.A. Leiter et al. DIABETES & METABOLISM
- Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention
- (2016) Eduardo Vilar-Gomez et al. HEPATOLOGY
- The independent predictors of non-alcoholic steatohepatitis and its individual histological features.
- (2016) Stefano Ballestri et al. HEPATOLOGY RESEARCH
- Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long–Evans Tokushima fatty rats
- (2016) Norihisa Nishimura et al. JOURNAL OF GASTROENTEROLOGY
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
- (2015) Yuka Hayashizaki-Someya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus:post hocsubgroup analyses according to body mass index in a 52-week open-label study
- (2015) Nobuya Inagaki et al. EXPERT OPINION ON PHARMACOTHERAPY
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2015) Sumio Watanabe et al. JOURNAL OF GASTROENTEROLOGY
- Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
- (2014) Nobuya Inagaki et al. EXPERT OPINION ON PHARMACOTHERAPY
- Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients
- (2014) Yuya Seko et al. HEPATOLOGY RESEARCH
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study
- (2014) Nobuya Inagaki et al. Journal of Diabetes Investigation
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study
- (2013) N. Inagaki et al. DIABETES OBESITY & METABOLISM
- Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients
- (2013) Takashi Nakahara et al. JOURNAL OF GASTROENTEROLOGY
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- (2012) Naga Chalasani et al. HEPATOLOGY
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
- (2011) G. Vernon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Renal glucose reabsorption inhibitors to treat diabetes
- (2011) Clifford J. Bailey TRENDS IN PHARMACOLOGICAL SCIENCES
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- (2010) Christopher D. Williams et al. GASTROENTEROLOGY
- Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
- (2010) Herbert Tilg et al. HEPATOLOGY
- Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus
- (2010) Nathalie C. Leite et al. LIVER INTERNATIONAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search